The Voice of the Industry
06/23/2025
New in Contract Pharma: Enabling the Outcome Through End-to-End Supply Chain Excellence
Cryoport Systems is featured in Contract Pharma with an article discussing the benefits of a unified, end-to-end supply chain platform for advanced therapies. Titled "Enabling the Outcome: The Power of an End-to-End Supply Chain Platform for Advanced Therapies," the piece highlights the growing demand from advanced therapy sponsors, CDMOs, and clinical partners for integrated solutions that encompass logistics, BioServices, biostorage, and consulting in one partnership.
06/09/2025
Cryoport Systems Nominated for Three APCGTEA Awards
Cryoport Systems has been officially nominated for three prestigious categories in the 2025 Asia-Pacific Cell & Gene Therapy Excellence Awards (APCGTEA). These nominations highlight the strength of our innovation, commitment to quality, and enduring partnership with the advanced therapies community across the region.
05/19/2025
Addressing the EMEA Cold Chain Challenge for Cell and Gene Therapies: Cryoport Systems Featured in Labiotech.eu
In a recent Labiotech.eu article, Florent Belon, Managing Director for Cryoport Systems in France, discusses how regulatory diversity, infrastructure gaps, and extreme climate variation across EMEA intensify the need for customized, compliant cold chain solutions.
05/01/2025
New Article with Contract Pharma: Minimizing Capital Expenditures through Supply Chain Integration
Cryoport Systems has been featured in a new Contract Pharma article, “Minimizing Capital Expenditures through Supply Chain Integration.” This article explores how an integrated supply chain partner like Cryoport Systems helps organizations reduce risk, preserve capital, and gain the flexibility to scale without the burden of building it all themselves.
04/22/2025
Cryoport Systems Featured in Contract Pharma: The Power of an Integrated Supply Chain
Contract Pharma recently featured Cryoport Systems in a new Q&A article spotlighting our integrated, end-to-end supply chain platform for cell and gene therapies. The piece highlights insights from Matthew Frazzetta, Vice President of Global Accounts, BioServices at Cryoport Systems, and explores how we are supporting the growing needs of life sciences companies around the world.
03/26/2025
CEO Mark Sawicki in Pharma Focus Asia on the Future of Cell & Gene Therapy
The cell and gene therapy (CGT) industry continues to introduce new breakthroughs shaping the future of medicine. In the latest issue of Pharma Focus Asia, Cryoport Systems’ CEO, Mark Sawicki, Ph.D., shares his expert insights on the key drivers of growth, the importance of standardization, and the critical role of a scalable supply chain in advancing the industry.
02/04/2025
Cryoport Systems’ HV3 Cryogenic Shipping System Featured in International Hospital
Cryoport Systems’ latest innovation, the Cryoport Express® Cryogenic HV3 Shipping System, was recently highlighted in International Hospital, recognizing its impact on temperature-controlled logistics for advanced therapies.
01/31/2025
